Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
Normal
none of this is true. M184v is in about half the population plwhiv and tests miss it half the time. You are literally setting patients up for failure on dovavto then success with Biktarvy. The clinical trials gilead has encompasses all patients, sub types and challenging patients. Viiv trials excluded and cherry picked as usual. this isn’t the competition anyway as dovato is used about 1% of the time which makes sense. No need to argue as it’s basically today’s viramune...maybe a few patients are a good choice but most are not.
none of this is true. M184v is in about half the population plwhiv and tests miss it half the time. You are literally setting patients up for failure on dovavto then success with Biktarvy. The clinical trials gilead has encompasses all patients, sub types and challenging patients. Viiv trials excluded and cherry picked as usual.
this isn’t the competition anyway as dovato is used about 1% of the time which makes sense. No need to argue as it’s basically today’s viramune...maybe a few patients are a good choice but most are not.
